Drug
Nintedanib (OFEV®)
Status:
To Patients
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Nintedanib (OFEV®) is an anti-fibrotic drug that is approved to treat idiopathic pulmonary fibrosis in the United States, Europe, and Australia. In clinical trials, nintedanib has been shown to slow the decline in lung function in mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth twice a day.